Most Read Articles
5 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 6 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 3 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.
Yesterday
Monotherapy with tocilizumab (TCZ) shows good tolerability profile and results in remission in most patients with polymyalgia rheumatica (PMR) despite the absence of glucocorticoids, according to the 2-year results of a single-centre, open‐label pilot study.

HPV vaccine uptake low, HCPs highlight strategies to improve coverage

Roshini Claire Anthony
17 May 2019

The low uptake of the human papillomavirus (HPV) vaccine in the US and strategies to improve HPV vaccine coverage were highlighted in two studies presented at the Pediatric Academic Societies annual meeting (PAS 2019).

Researchers from the Harvard T.H. Chan School of Public Health and Harvard Medical School in Boston, Massachusetts, US, used the Truven MarketScan healthcare database between 2003 and 2016 to identify 7,500,397 children (49 percent female) who were followed from the year they turned age 9 years until they received their first dose of the HPV vaccine, end of the year when they turned age 17 years, end of insurance coverage, or death, whichever was first (18.8 million person-years).

The proportion of 15-year-olds who had received 1 dose of the HPV vaccine increased between 2011 and 2016, among girls (from 37.8 to 53.6 percent) and boys (from 4.8 to 45.1 percent). [PAS 2019, publication number 3350.4]

Despite the increase between these years, HPV vaccine coverage still falls short, said study author Dr Chen Szu-Ta from the Harvard T.H. Chan School of Public Health.

“[T]he HPV vaccine coverage varied substantially between states and remained behind the Healthy People 2020 goal of 80 percent,” he said, highlighting that coverage exceeding 60 percent among girls and boys aged 15 years only occurred in 13 and three states, respectively, by 2016.

 

Identifying barriers to HPV vaccine coverage

Several barriers to HPV vaccine uptake were identified through surveys completed by the lead practitioner from 47 practices (from 19 states in the US) in the Pediatric Research in Office Settings (PROS) network.

In this study, a sub-study of the STOP HPV trial, all practitioners reported facing barriers to HPV vaccination, the most common being parental refusal or delay which exceeded 80 percent. About 30 percent of parents of 11- to 12-year-olds refused the HPV vaccine for their children, while 15 percent were hesitant. [PAS 2019, publication number 3335.1]

Seventeen percent of practitioners reported that the lack of time to discuss HPV vaccination was a barrier to vaccine uptake, as was the low number of adolescents who present at “well visits” and the lack of training on how to strongly recommend the HPV vaccine (13 and 11 percent, respectively). Other barriers were the opinion that the HPV vaccine could be delayed (9 percent) and difficulty administering the vaccine when patients presented with other health complaints (acute or chronic care visits; 7 percent).

 

Strategies to improve coverage

Among the more common strategies to improve HPV uptake were using prompts to inform patients on the need for the HPV vaccine, using tools to communicate with adolescents and their parents on the HPV vaccine, and receiving “performance feedback” on HPV vaccination rates (89, 87, and 83 percent, respectively).

Despite the multiple strategies used, senior study author Dr Alexander Fiks from the Children’s Hospital of Philadelphia in Philadelphia, Pennsylvania, US, pointed out that there was still “room for improvement”.

“The ongoing STOP HPV trial will test the effectiveness of distinct strategies, alone or in combination, to overcome barriers to vaccination and, if effective, may ultimately minimize the burden of HPV-related disease,” he said.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 6 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 3 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.
Yesterday
Monotherapy with tocilizumab (TCZ) shows good tolerability profile and results in remission in most patients with polymyalgia rheumatica (PMR) despite the absence of glucocorticoids, according to the 2-year results of a single-centre, open‐label pilot study.